OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 18:42:51 29/04/2024 BST | ||
| 6.78 EUR / 6.81 EUR | +0.22% |
|
| Current month | +28.65% | ||
| 1 month | +37.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 6.78 | 0.00% | 0 |
| 26/04/24 | 6.78 | +0.74% | 0 |
| 25/04/24 | 6.73 | +13.11% | 0 |
| 24/04/24 | 5.95 | +1.88% | 0 |
| 23/04/24 | 5.84 | -1.18% | 0 |
Delayed Quote Börse Stuttgart
Last update April 29, 2024 at 06:11 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6Z79 |
| ISIN | DE000HR6Z791 |
| Date issued | 21/04/2021 |
| Strike | 6,226 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.28 € |
|---|---|
| Lowest since issue | 2.05 € |
| Spread | 0.03 € |
| Spread % | 0.44% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
- Stock Market
- Certificates
- Certificat
